IL187328A - N- Methyl-2-Fluoro- {4- [3- (4-Cyano-3-Trifluoromethylphenyl) -5,5-Dimethyl-4-Oxo-2-Theoxo-Imidazolidin-1-Ill]} Benzamide, Pharmaceuticals Containing It and its use for drug preparation - Google Patents

N- Methyl-2-Fluoro- {4- [3- (4-Cyano-3-Trifluoromethylphenyl) -5,5-Dimethyl-4-Oxo-2-Theoxo-Imidazolidin-1-Ill]} Benzamide, Pharmaceuticals Containing It and its use for drug preparation

Info

Publication number
IL187328A
IL187328A IL187328A IL18732807A IL187328A IL 187328 A IL187328 A IL 187328A IL 187328 A IL187328 A IL 187328A IL 18732807 A IL18732807 A IL 18732807A IL 187328 A IL187328 A IL 187328A
Authority
IL
Israel
Prior art keywords
imidazolidin
thioxo
trifluoromethylphenyl
benzamide
medicaments
Prior art date
Application number
IL187328A
Other languages
English (en)
Hebrew (he)
Other versions
IL187328A0 (en
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37431537&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL187328(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ California filed Critical Univ California
Publication of IL187328A0 publication Critical patent/IL187328A0/en
Publication of IL187328A publication Critical patent/IL187328A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/86—Oxygen and sulfur atoms, e.g. thiohydantoin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/45—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C255/46—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of non-condensed rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C317/34—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring
    • C07C317/36—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring with the nitrogen atoms of the amino groups bound to hydrogen atoms or to carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C331/00—Derivatives of thiocyanic acid or of isothiocyanic acid
    • C07C331/16—Isothiocyanates
    • C07C331/28—Isothiocyanates having isothiocyanate groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/88—Nitrogen atoms, e.g. allantoin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Macromonomer-Based Addition Polymer (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)
IL187328A 2005-05-13 2007-11-12 N- Methyl-2-Fluoro- {4- [3- (4-Cyano-3-Trifluoromethylphenyl) -5,5-Dimethyl-4-Oxo-2-Theoxo-Imidazolidin-1-Ill]} Benzamide, Pharmaceuticals Containing It and its use for drug preparation IL187328A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US68083505P 2005-05-13 2005-05-13
US75035105P 2005-12-15 2005-12-15
US75655206P 2006-01-06 2006-01-06
PCT/US2006/011417 WO2006124118A1 (en) 2005-05-13 2006-03-29 Diarylhydantoin compounds

Publications (2)

Publication Number Publication Date
IL187328A0 IL187328A0 (en) 2008-04-13
IL187328A true IL187328A (en) 2016-02-29

Family

ID=37431537

Family Applications (4)

Application Number Title Priority Date Filing Date
IL187328A IL187328A (en) 2005-05-13 2007-11-12 N- Methyl-2-Fluoro- {4- [3- (4-Cyano-3-Trifluoromethylphenyl) -5,5-Dimethyl-4-Oxo-2-Theoxo-Imidazolidin-1-Ill]} Benzamide, Pharmaceuticals Containing It and its use for drug preparation
IL243812A IL243812A0 (en) 2005-05-13 2016-01-28 Compounds of diarylhydantoin
IL258880A IL258880A (en) 2005-05-13 2018-04-23 Diarylhydantoin compounds
IL323480A IL323480A (en) 2005-05-13 2025-09-21 Diarylhydantoin compounds

Family Applications After (3)

Application Number Title Priority Date Filing Date
IL243812A IL243812A0 (en) 2005-05-13 2016-01-28 Compounds of diarylhydantoin
IL258880A IL258880A (en) 2005-05-13 2018-04-23 Diarylhydantoin compounds
IL323480A IL323480A (en) 2005-05-13 2025-09-21 Diarylhydantoin compounds

Country Status (29)

Country Link
EP (5) EP3106162A1 (enExample)
JP (13) JP4644737B2 (enExample)
KR (12) KR101332924B1 (enExample)
CN (6) CN116003328A (enExample)
AT (1) ATE541571T1 (enExample)
AU (1) AU2006248109B2 (enExample)
BE (1) BE2013C074I2 (enExample)
BR (1) BRPI0610359B8 (enExample)
CA (1) CA2608436C (enExample)
CY (2) CY1112798T1 (enExample)
DK (2) DK1893196T4 (enExample)
ES (2) ES2535179T3 (enExample)
HK (1) HK1217103A1 (enExample)
HR (2) HRP20120323T4 (enExample)
HU (1) HUS1300076I1 (enExample)
IL (4) IL187328A (enExample)
LU (1) LU92338I2 (enExample)
ME (1) ME01992B (enExample)
MX (4) MX2007014132A (enExample)
NO (4) NO339997B1 (enExample)
NZ (3) NZ710355A (enExample)
PL (2) PL2444085T3 (enExample)
PT (2) PT1893196E (enExample)
RS (2) RS53967B1 (enExample)
RU (3) RU2448096C3 (enExample)
SG (1) SG10201703816SA (enExample)
SI (2) SI2444085T1 (enExample)
WO (1) WO2006124118A1 (enExample)
ZA (2) ZA200710870B (enExample)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602004031881D1 (de) 2003-12-19 2011-04-28 Univ California Verfahren und materialien zur beurteilung von prostatakrebstherapien
NZ550102A (en) 2004-02-24 2010-10-29 Univ California Methods and materials for assessing prostate cancer therapies and compounds (thiohydantoine derivatives)
AU2007245022A1 (en) * 2006-03-29 2007-11-08 The Regents Of The University Of California Diarylthiohydantoin compounds
CA2608436C (en) * 2005-05-13 2015-03-24 The Regents Of The University Of California Diarylhydantoin compounds and their use in the treatment of hyperproliferative disorders
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
EP3100727B1 (en) 2006-03-27 2018-08-22 The Regents of The University of California Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases
WO2008093838A1 (ja) * 2007-02-01 2008-08-07 Chugai Seiyaku Kabushiki Kaisha スルファモイル基を有するピリジルイミダゾリジン誘導体、およびその医薬としての使用
WO2008119015A2 (en) 2007-03-27 2008-10-02 Sloan-Kettering Institute For Cancer Research Synthesis of thiohydantoins
EP2397469B1 (en) * 2007-10-26 2014-12-31 The Regents of The University of California Diarylhydantoin compounds
CN102421291A (zh) * 2009-02-24 2012-04-18 梅迪维新前列腺医疗股份有限公司 具体的二芳基乙内酰脲和二芳基乙内酰硫脲化合物
CN101817787B (zh) * 2009-02-26 2013-07-24 童友之 抗前列腺癌的雄性激素受体拮抗剂
JP2012526544A (ja) * 2009-05-12 2012-11-01 コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ 悪性のホルモン感受性前立腺がんのマーカーとしてのホスホジエステラーゼ４ｄ７
CA2772579C (en) 2009-09-10 2015-12-08 Youzhi Tong Thioimidazolidinone androgen receptor antagonists and uses thereof
JP2013504531A (ja) 2009-09-11 2013-02-07 バイエル・ファルマ・アクチェンゲゼルシャフト 抗癌薬としての置換（ヘテロアリールメチル）チオヒダントイン
TW201111378A (en) * 2009-09-11 2011-04-01 Bayer Schering Pharma Ag Substituted (heteroarylmethyl) thiohydantoins
AR078793A1 (es) 2009-10-27 2011-12-07 Orion Corp Derivados de carboxamidas no esteroidales y acil hidrazona moduladores de receptores androgenicos de tejido selectivo (sarm), composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer de prostata entre otros
BR112012015868A2 (pt) 2009-12-11 2017-06-20 Autifony Therapeutics Ltd derivados de imidazolidinadiona
SI3124481T1 (en) 2010-02-16 2018-06-29 Aragon Pharmaceuticals, Inc. Androgen receptor modulators and their use
BR112012021406B1 (pt) * 2010-02-24 2021-08-10 Medivation Prostate Therapeutics Llc Processos para a síntese dos compostos de diariltioidantoína e diarilidantoína
RU2434851C1 (ru) * 2010-07-22 2011-11-27 Александр Васильевич Иващенко Циклические n, n'-диарилтиомочевины или n, n'-диарилмочевины - антагонисты андрогенных рецепторов, противораковое средство, способ получения и применения
SG190203A1 (en) 2010-12-06 2013-06-28 Autifony Therapeutics Ltd Hydantoin derivatives useful as kv3 inhibitors
JP5833681B2 (ja) 2011-03-10 2015-12-16 蘇州開拓薬業有限公司Ｓｕｚｈｏｕｋｉｎｔｏｒ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． アンドロゲン受容体アンタゴニストおよびその使用
JP5964407B2 (ja) 2011-04-21 2016-08-03 オリオン コーポレーション アンドロゲン受容体調節カルボキシアミド
EP2718285B1 (en) 2011-06-07 2016-03-16 Autifony Therapeutics Limited Hydantoin derivatives as kv3 inhibitors
EP2739153B1 (en) * 2011-07-29 2018-08-22 Medivation Prostate Therapeutics LLC Treatment of breast cancer
JP6309454B2 (ja) 2011-11-30 2018-04-11 アストラゼネカ アクチボラグ 癌の併用処置
CN103159680A (zh) 2011-12-14 2013-06-19 爱美尼迪药物有限公司 咪唑二酮类化合物及其用途
AU2013204533B2 (en) 2012-04-17 2017-02-02 Astrazeneca Ab Crystalline forms
WO2013175211A1 (en) 2012-05-22 2013-11-28 Autifony Therapeutics Limited Hydantoin derivatives as kv3 inhibitors
US9422252B2 (en) 2012-05-22 2016-08-23 Autifony Therapeutics Limited Triazoles as Kv3 inhibitors
RU2639145C2 (ru) * 2012-09-04 2017-12-20 Шанхай Хэнжуй Фармасьютикал Ко., Лтд. Производные оксотиоимидазолидина, способы их получения и их применение в медицине в качестве ингибиторов андрогенного рецептора
ES2892029T3 (es) 2012-09-11 2022-02-01 Medivation Prostate Therapeutics Llc Formulaciones de enzalutamida
EP2895464A4 (en) * 2012-09-11 2016-06-15 Reddys Lab Ltd Dr POLYMORPHIC ENZALUTAMIDE FORMS AND THEIR PREPARATION
EA030128B1 (ru) 2012-09-26 2018-06-29 Арагон Фармасьютикалз, Инк. Способ лечения неметастатического кастрационно-резистентного рака простаты
US9944607B2 (en) 2012-10-16 2018-04-17 Whitehead Institute For Biomedical Research Thiohydantoin derivatives and uses thereof
CA2889756C (en) * 2012-10-26 2023-03-14 Memorial Sloan-Kettering Cancer Center Thiohydantoin compounds as androgen receptor modulators
JOP20200097A1 (ar) 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته
RU2520134C1 (ru) * 2013-02-27 2014-06-20 Общество с ограниченной ответственностью "Авионко" (ООО "Авионко") Замещенные (r)-3-(4-метилкарбамоил-3-фторфениламино)-тетрагидро-фуран-3-енкарбоновые кислоты и их эфиры, способ их получения и применения
WO2014167428A2 (en) * 2013-04-10 2014-10-16 Shilpa Medicare Limited Amorphous 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-n-methylbenzamide
CN105722830B (zh) 2013-06-20 2019-06-04 拜耳作物科学股份公司 作为杀螨剂和杀昆虫剂的芳基硫醚衍生物和芳基亚砜衍生物
WO2015018356A1 (zh) * 2013-08-08 2015-02-12 上海医药集团股份有限公司 二芳基乙内酰脲衍生物、其制备方法、药物组合物和应用
WO2015042170A1 (en) 2013-09-17 2015-03-26 Wayne State University Compositions and uses of combinations of dim-related indoles and selected anti-androgen compounds
RU2016110546A (ru) * 2013-09-19 2017-10-24 ГЛАКСОСМИТКЛАЙН ЭлЭлСи Комбинированная лекарственная терапия
CN105188699B (zh) * 2013-10-14 2017-04-26 杭州普晒医药科技有限公司 恩杂鲁胺的固态形式及其制备方法和用途
EP3063135A1 (en) 2013-10-31 2016-09-07 Sun Pharmaceutical Industries Ltd Process for the preparation of enzalutamide
EP3083568A1 (en) 2013-12-16 2016-10-26 Sun Pharmaceutical Industries Ltd Processes and intermediates for the preparation of enzalutamide
US9682960B2 (en) 2013-12-19 2017-06-20 Endorecherche, Inc. Non-steroidal antiandrogens and selective androgen receptor modulators with a pyridyl moiety
CN104803919A (zh) * 2014-01-26 2015-07-29 上海医药工业研究院 用于制备恩杂鲁胺中间体的方法
EP3105208A1 (en) 2014-02-13 2016-12-21 Ranbaxy Laboratories Limited Process for the preparation of enzalutamide
CZ2014232A3 (cs) 2014-04-07 2015-10-14 Zentiva, K.S. Způsob výroby enzalutamidu
CN103896847B (zh) * 2014-04-09 2016-01-20 沈江 一种非甾体类抗雄激素化合物及其制备方法和应用
CN103910679B (zh) * 2014-04-23 2016-05-25 杭州新博思生物医药有限公司 一种恩杂鲁胺的制备方法
CN104003939B (zh) * 2014-06-06 2017-07-07 山东大学 二芳基取代乙内酰硫脲类化合物及其制备方法与应用
CN104016924B (zh) * 2014-06-16 2016-04-13 上海鼎雅药物化学科技有限公司 一种“一锅法”合成恩杂鲁胺的方法
WO2015196144A2 (en) 2014-06-20 2015-12-23 England Pamela M Androgen receptor antagonists
RU2557235C1 (ru) * 2014-07-08 2015-07-20 Александр Васильевич Иващенко Замещенные 2-тиоксо-имидазолидин-4-оны и их спироаналоги, противораковый активный компонент, фармацевтическая композиция, лекарственный препарат, способ лечения рака простаты
WO2016005875A1 (en) * 2014-07-11 2016-01-14 Shilpa Medicare Limited An improved process for the preparation of enzalutamide
EP4494636A3 (en) 2014-12-05 2025-04-30 Aragon Pharmaceuticals, Inc. Anticancer compositions
WO2016094408A1 (en) 2014-12-12 2016-06-16 Medivation Prostate Therapeutics, Inc. Method for predicting response to breast cancer therapeutic agents and method of treatment of breast cancer
CN104610111A (zh) * 2014-12-26 2015-05-13 杭州和泽医药科技有限公司 一种4-异硫代氰酰基-2-(三氟甲基)苯甲腈的制备方法
CN105523958B (zh) * 2015-01-13 2017-11-03 北京海步医药科技股份有限公司 一种制备二芳基硫代乙内酰脲衍生物关键中间体的方法
CN107428734A (zh) * 2015-01-20 2017-12-01 阿尔维纳斯股份有限公司 用于雄激素受体的靶向降解的化合物和方法
US12312316B2 (en) 2015-01-20 2025-05-27 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
CN106187905B (zh) * 2015-05-05 2020-02-21 北京海步医药科技股份有限公司 丁鲁他胺的结晶形式及其制备方法
ITUB20151204A1 (it) 2015-05-28 2016-11-28 Olon Spa Procedimento per la preparazione di enzalutamide
ITUB20151256A1 (it) 2015-05-28 2016-11-28 Olon Spa Processo industriale per la preparazione di enzalutamide
ITUB20151311A1 (it) * 2015-05-28 2016-11-28 Olon Spa Procedimento per la preparazione di enzalutamide
PL3305770T3 (pl) 2015-05-29 2023-06-26 Astellas Pharma Inc. Sposób wytwarzania postaci krystalicznej enzalutamidu
SI3348546T1 (sl) 2015-09-10 2020-09-30 Jiangsu Hengrui Medicine Co., Ltd. Kristalinična oblika zaviralca androgenega receptorja in postopek priprave le-tega
TWI726969B (zh) 2016-01-11 2021-05-11 比利時商健生藥品公司 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
WO2018009694A1 (en) * 2016-07-08 2018-01-11 Janssen Pharmaceutica Nv Thiohydantoin androgen receptor antagonists for the treatment of cancer
KR102368555B1 (ko) 2016-12-16 2022-02-28 강푸 바이오파마슈티칼즈 리미티드 조성물, 이의 적용 및 치료 방법
CN110573153B (zh) 2017-04-28 2023-04-04 安斯泰来制药有限公司 含有恩杂鲁胺的口服给药用药物组合物
NZ763947A (en) 2017-10-16 2025-12-19 Aragon Pharmaceuticals Inc Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer
US10513504B2 (en) 2018-03-08 2019-12-24 Apotex Inc. Processes for the preparation of apalutamide and intermediates thereof
CZ2018234A3 (cs) 2018-05-21 2019-12-04 Zentiva Ks Zvýšení rozpustnosti a biodostupnosti enzalutamidu
CN108976171B (zh) * 2018-08-27 2020-06-16 长沙泽达医药科技有限公司 化合物、组合物及其在药物制备中的用途
JP2022509917A (ja) 2018-11-05 2022-01-25 ファイザー・インク がんを処置するための組合せ
AU2019387370A1 (en) 2018-11-30 2021-06-10 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
EP3886853A4 (en) 2018-11-30 2022-07-06 Nuvation Bio Inc. DIARYLHYDANTOI COMPOUNDS AND METHODS OF USE THEREOF
CN109796437B (zh) * 2019-02-26 2021-08-24 上海健康医学院 具有ar和hdac双重抑制作用的乙内酰脲类和乙内酰硫脲类化合物及用途
CA3143111A1 (en) 2019-06-27 2020-12-30 Synthon B.V. Process for preparation of enzalutamide
CN110452166A (zh) * 2019-09-06 2019-11-15 浙江朗华制药有限公司 一种5-异硫氰酰基-3-三氟甲基-2-氰基吡啶的制备方法
WO2021064123A1 (en) 2019-10-03 2021-04-08 Synthon B.V. Pharmaceutical composition comprising enzalutamide
WO2021240206A1 (en) 2020-05-24 2021-12-02 Lotus International Pte. Ltd. Enzalutamide formulation
KR20230057384A (ko) 2020-08-13 2023-04-28 화이자 인코포레이티드 조합 요법
AR124199A1 (es) 2020-12-11 2023-02-22 Ildong Pharmaceutical Co Ltd Nuevos compuestos como inhibidor dual del receptor de andrógenos y de la fosfodiesterasa
JP2024510666A (ja) 2021-03-24 2024-03-08 ファイザー・インク Ｄｄｒ遺伝子変異転移性去勢感受性前立腺がんを処置するためのタラゾパリブおよび抗アンドロゲンの組合せ
EP4112603A1 (en) 2021-06-29 2023-01-04 Química Sintética, S.A. Processes for the preparation of non-steroidal antiandrogens
KR102861133B1 (ko) 2021-10-13 2025-09-16 주식회사 엘지에너지솔루션 배터리 충방전 프로파일 분석 방법 및 배터리 충방전 프로파일 분석 장치
CN114181155A (zh) * 2021-12-21 2022-03-15 上海朝晖药业有限公司 碘-恩杂鲁胺及其制备方法及其应用
CN117164520B (zh) * 2022-01-28 2025-04-25 南京思聚生物医药有限公司 一种局部作用的雄激素受体拮抗剂及其应用
KR20230170859A (ko) 2022-06-11 2023-12-19 이태영 패스트칫솔
TWI883565B (zh) 2022-10-02 2025-05-11 美商輝瑞大藥廠 用於治療轉移性去勢抵抗性前列腺癌之他拉唑帕尼及恩雜魯胺之組合
EP4374853A1 (en) 2022-11-22 2024-05-29 Lotus Pharmaceutical Co., Ltd. Solid formulation of enzalutamide
TW202425976A (zh) 2022-12-17 2024-07-01 美商輝瑞大藥廠 用於治療轉移性去勢抵抗性前列腺癌之他拉唑帕尼及恩雜魯胺之組合
CN115850186B (zh) * 2023-02-07 2024-04-09 长沙泽达医药科技有限公司 一种乙撑硫脲衍生物的晶型及用途
WO2025125565A1 (en) 2023-12-13 2025-06-19 Krka, D.D., Novo Mesto Tablet comprising enzalutamide
WO2025210510A1 (en) 2024-04-04 2025-10-09 Pfizer Inc. Tmprss2-erg and rb1 as predictive biomarkers for treatment with a parp inhibitor

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2329276A1 (fr) 1975-10-29 1977-05-27 Roussel Uclaf Nouvelles imidazolidines substituees, procede de preparation, application comme medicament et compositions les renfermant
ZA839023B (en) * 1982-12-06 1985-07-31 Pfizer Spiro-3-hetero-azolones for treatment of diabetic complications
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
FR2671348B1 (fr) 1991-01-09 1993-03-26 Roussel Uclaf Nouvelles phenylimidazolidines, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant.
US5411981A (en) * 1991-01-09 1995-05-02 Roussel Uclaf Phenylimidazolidines having antiandrogenic activity
FR2693461B1 (fr) * 1992-07-08 1994-09-02 Roussel Uclaf Nouvelles phénylimidazolidines substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
FR2694290B1 (fr) * 1992-07-08 1994-09-02 Roussel Uclaf Nouvelles phénylimidazolidines éventuellement substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
FR2715402B1 (fr) * 1994-01-05 1996-10-04 Roussel Uclaf Nouvelles phénylimidazolines éventuellement substituées, leur procédé et des intermédiaires de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
CA2181358A1 (en) † 1994-01-21 1995-07-27 Nancy M. Gray Methods and compositions for treating androgen-dependent diseases using optically pure r-(-)-casodex
FR2725206B1 (fr) 1994-09-29 1996-12-06 Roussel Uclaf Nouvelles imidazolidines substituees par un heterocycle, leur procede et des intermediaires de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant
US5656651A (en) 1995-06-16 1997-08-12 Biophysica Inc. Androgenic directed compositions
FR2741342B1 (fr) † 1995-11-22 1998-02-06 Roussel Uclaf Nouvelles phenylimidazolidines fluorees ou hydroxylees, procede, intermediaires de preparation, application comme medicaments, nouvelle utilisation et compositions pharmaceutiques
BR9914018A (pt) 1998-09-22 2001-07-03 Yamanouchi Pharmaceuticals Co Derivado de cianofenila
FR2796945B1 (fr) * 1999-07-30 2002-06-28 Sod Conseils Rech Applic Nouveaux derives d'hydantoines, de thiohydantoines, de pyrimidinediones et de thioxopyrimidinones, leurs procedes de preparation et leur application a titre de medicaments
US6861432B2 (en) 2001-11-23 2005-03-01 Schering Aktiengesellschaft Piperazine derivatives that destabilize androgen receptors
EP1546111A2 (fr) 2002-10-04 2005-06-29 Laboratoires Fournier S.A. Composes derives de la 2-thiohydantoine et leur utilisation pour le traitement du diabete
FR2850652B1 (fr) 2003-01-31 2008-05-30 Aventis Pharma Sa Nouveaux derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
US20050005529A1 (en) 2003-07-10 2005-01-13 David Brault Lighting system for a greenhouse
NZ550102A (en) * 2004-02-24 2010-10-29 Univ California Methods and materials for assessing prostate cancer therapies and compounds (thiohydantoine derivatives)
CA2579886A1 (en) * 2004-09-09 2006-03-16 Chugai Seiyaku Kabushiki Kaisha Novel imidazolidine derivative and use thereof
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
CA2608436C (en) * 2005-05-13 2015-03-24 The Regents Of The University Of California Diarylhydantoin compounds and their use in the treatment of hyperproliferative disorders

Also Published As

Publication number Publication date
HK1169321A1 (en) 2013-01-25
JP2025166151A (ja) 2025-11-05
KR101515335B1 (ko) 2015-04-24
MX394667B (es) 2025-03-21
SI2444085T1 (sl) 2015-06-30
MX2007014132A (es) 2008-04-09
DK1893196T4 (en) 2015-10-19
HRP20150437T1 (xx) 2015-06-05
MX346924B (es) 2017-04-05
HK1112856A1 (en) 2008-09-19
HRP20120323T1 (en) 2012-05-31
BE2013C074I2 (enExample) 2025-09-17
JP2016183200A (ja) 2016-10-20
KR20080014039A (ko) 2008-02-13
BRPI0610359B8 (pt) 2021-05-25
JP2011068653A (ja) 2011-04-07
EP2561871A1 (en) 2013-02-27
DK1893196T3 (da) 2012-04-10
JP2018100292A (ja) 2018-06-28
RS52274B2 (sr) 2018-05-31
JP2015098497A (ja) 2015-05-28
IL258880A (en) 2018-06-28
JP5150780B2 (ja) 2013-02-27
KR20230003445A (ko) 2023-01-05
ATE541571T1 (de) 2012-02-15
PL1893196T3 (pl) 2012-06-29
IL187328A0 (en) 2008-04-13
NO20076401L (no) 2008-02-08
IL243812A0 (en) 2016-04-21
JP2022101657A (ja) 2022-07-06
KR102713358B1 (ko) 2024-10-02
KR20190104244A (ko) 2019-09-06
HUS1300076I1 (hu) 2013-12-17
EP3970721A1 (en) 2022-03-23
KR101332889B1 (ko) 2013-11-26
JP2024153705A (ja) 2024-10-29
JP6013535B2 (ja) 2016-10-25
KR102324567B1 (ko) 2021-11-09
JP2008540523A (ja) 2008-11-20
EP2444085B1 (en) 2015-03-18
CY2013047I1 (el) 2015-11-04
AU2006248109B2 (en) 2012-11-15
KR102020721B1 (ko) 2019-09-10
BRPI0610359B1 (pt) 2020-09-24
ES2378778T3 (es) 2012-04-17
KR20120102140A (ko) 2012-09-17
JP2012211190A (ja) 2012-11-01
SI1893196T2 (sl) 2015-10-30
SI1893196T1 (sl) 2012-06-29
CN110003114B (zh) 2023-01-17
EP1893196B2 (en) 2015-07-29
LU92338I2 (fr) 2015-10-27
NO342490B1 (no) 2018-06-04
CN101222922B (zh) 2012-04-18
DK2444085T3 (en) 2015-04-27
JP2021035970A (ja) 2021-03-04
PL1893196T5 (pl) 2015-12-31
CN120682155A (zh) 2025-09-23
CN105037273B (zh) 2019-04-19
RU2007146462A (ru) 2009-06-20
KR20130060369A (ko) 2013-06-07
BRPI0610359A2 (pt) 2010-06-15
KR20140141676A (ko) 2014-12-10
RU2448096C2 (ru) 2012-04-20
EP2444085A1 (en) 2012-04-25
PT2444085E (pt) 2015-06-11
RU2017142159A (ru) 2019-06-05
AU2006248109A1 (en) 2006-11-23
EP1893196A1 (en) 2008-03-05
HRP20120323T4 (hr) 2015-10-09
NO20161996A1 (no) 2008-02-08
NO339997B1 (no) 2017-02-27
CN110003114A (zh) 2019-07-12
NO2017019I1 (no) 2017-05-04
CY2013047I2 (el) 2015-11-04
JP4644737B2 (ja) 2011-03-02
ZA200710870B (en) 2012-06-27
CN105037273A (zh) 2015-11-11
CY1112798T1 (el) 2015-11-04
KR102481886B1 (ko) 2022-12-28
KR20140041831A (ko) 2014-04-04
NZ564223A (en) 2011-03-31
ME01992B (me) 2012-10-30
KR20150086567A (ko) 2015-07-28
KR20240148945A (ko) 2024-10-11
EP1893196B1 (en) 2012-01-18
KR101332924B1 (ko) 2013-11-26
NO20180225A1 (no) 2008-02-08
CN116003328A (zh) 2023-04-25
PT1893196E (pt) 2012-04-03
JP5138753B2 (ja) 2013-02-06
JP2023075313A (ja) 2023-05-30
NO2017019I2 (no) 2017-05-04
KR20170107585A (ko) 2017-09-25
RU2448096C3 (ru) 2017-12-11
KR101169832B1 (ko) 2012-07-30
ES2378778T5 (es) 2015-09-25
KR20210136161A (ko) 2021-11-16
CN101222922A (zh) 2008-07-16
JP2012236843A (ja) 2012-12-06
NZ591119A (en) 2012-08-31
CA2608436C (en) 2015-03-24
SG10201703816SA (en) 2017-06-29
MX2022009759A (es) 2022-09-05
EP1893196A4 (en) 2009-03-18
JP2019218352A (ja) 2019-12-26
KR101431407B1 (ko) 2014-08-18
RS53967B1 (sr) 2015-08-31
CN102584712A (zh) 2012-07-18
KR101782236B1 (ko) 2017-09-26
PL2444085T3 (pl) 2015-07-31
HK1217103A1 (zh) 2016-12-23
RS52274B (sr) 2012-10-31
MX2019015200A (es) 2020-02-05
ES2535179T3 (es) 2015-05-06
KR20110041580A (ko) 2011-04-21
IL323480A (en) 2025-11-01
NZ710355A (en) 2017-01-27
WO2006124118A1 (en) 2006-11-23
EP3106162A1 (en) 2016-12-21
CA2608436A1 (en) 2006-11-23
RU2638833C2 (ru) 2017-12-18
ZA201201793B (en) 2015-12-23
KR101579701B1 (ko) 2015-12-22

Similar Documents

Publication Publication Date Title
IL187328A (en) N- Methyl-2-Fluoro- {4- [3- (4-Cyano-3-Trifluoromethylphenyl) -5,5-Dimethyl-4-Oxo-2-Theoxo-Imidazolidin-1-Ill]} Benzamide, Pharmaceuticals Containing It and its use for drug preparation
MY147994A (en) Azabiphenylaminobenzoic acid derivatives as dhodh inhibitors
MX2007002398A (es) Nuevas composiciones farmaceuticas para el tratamiento de cancer.
TW200510325A (en) 2-acylamino-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof
GEP20125565B (en) Lactam compounds and their pharmaceutical use
MX2009007337A (es) Indazoles sustituidos con 5-piridinona.
TNSN07076A1 (en) New pharmaceutical compositions comprising 4-(4-(3-(4-chloro-3-trifluoromethyl-phenyl)-ureido)-3-fluoro-phenoxy-pyridine-2-carboxylic acid for the treatment of hyper-proliferative disorders
TNSN08370A1 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
GEP20084452B (en) Sulfonamide derivatives for the treatment of diseases
UA86977C2 (ru) Производные гидантоина для лечения обструктивных болезней дыхательных путей
MX272108B (es) Heterociclos sustituidos.
UA104988C2 (uk) Похідні піроніндолу та спосіб їх отримання
TW200738659A (en) Novel compounds
MY141528A (en) Anilinopyrazole derivatives useful for the treatment of diabetes
TW200724537A (en) Pyrimidine derivatives for treatment of hyperproliferative disorders
TW200745122A (en) New compounds I
WO2007076087A3 (en) 3-aryl-substituted quinazolones, and uses thereof
UA86399C2 (ru) Применение 2,5 дигидроксибензолсульфоновой кислоты для изготовления лекарства, которые применяют для лечения болезней, зависимых от ангиогенеза
TW200621703A (en) Alkylidene-tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents
TW200738611A (en) 9-Chloro-15-deoxyprostaglandin derivatives, process for their preparation and their use as medicaments
UA95780C2 (en) Xanthine derivatives as selective hm74a agonists
SI1904511T1 (sl) Homogemcitabini
UA95260C2 (ru) Производное 4-(3-аминопиразол)пиримидина и его применение для лечения злокачественного новообразования
UA93197C2 (ru) Производные пиразолиламинопиридина, способ их получения, их применения и фармацевтическая композиция (варианты)
UA99734C2 (ru) Производные азабифениламинобензойной кислоты как ингибиторы dhodh

Legal Events

Date Code Title Description
EXTF Application for patent extension filed

Filing date: 20160212

FF Patent granted
KB20 Patent renewed for 20 years
PEL Intention of commissioner to extend period of protection

Free format text: PRODUCT NAME: ENZALUTAMIDE

Extension date: 20260831

PEL Intention of commissioner to extend period of protection

Free format text: PRODUCT NAME: ENZALUTAMIDE

Extension date: 20260708

EXTG Extension of patent term granted

Extension date: 20260708